Fulgent Genetics Inc (FLGT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $688.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Fulgent Genetics Inc (FLGT) Earnings: Report Dates and Results
Fulgent Genetics (FLGT) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Fulgent Genetics reported EPS of -$0.09, above the -$0.65 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FLGT has an expected report date of Feb 25, 2027.
FLGT Earnings Call
The latest FLGT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, FLGT beat 24, missed 11 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $90.41M, up 7.5% from $84.07M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.09 | -$0.65 | -$0.65 - -$0.65 | +86.15% | Beat | -164.3% | 1 | 0 up, 0 down | Nov 5, 2026 | $90.41M |
| Jun 30, 2026 | -$0.88 | -$0.79 | N/A | -11.39% | Miss | -1357.1% | 2 | 0 up, 1 down | Jul 30, 2026 | $85.39M |
| Mar 31, 2026 | -$0.36 | -$0.35 | -$0.51 - -$0.19 | -2.86% | Miss | -1000.0% | 2 | 0 up, 0 down | May 1, 2026 | $71.14M |
| Dec 31, 2025 | $0.16 | -$0.06 | N/A | +365.78% | Beat | +300.0% | 3 | 1 up, 1 down | Feb 27, 2026 | $83.34M |
| Sep 30, 2025 | $0.14 | -$0.22 | -$0.27 - -$0.19 | +163.64% | Beat | -54.8% | 3 | 0 up, 2 down | Nov 7, 2025 | $84.07M |
| Jun 30, 2025 | $0.07 | -$0.18 | -$0.23 - -$0.10 | +138.89% | Beat | -53.3% | 3 | 1 up, 1 down | Aug 1, 2025 | $81.80M |
| Mar 31, 2025 | $0.04 | -$0.18 | -$0.23 - -$0.14 | +122.22% | Beat | N/A | 3 | 1 up, 1 down | May 2, 2025 | $73.46M |
| Dec 31, 2024 | $0.04 | -$0.37 | -$0.61 - -$0.13 | +110.84% | Beat | -85.7% | 2 | 1 up, 0 down | Feb 28, 2025 | $76.21M |
| Sep 30, 2024 | $0.31 | -$0.15 | -$0.19 - -$0.09 | +306.67% | Beat | N/A | 3 | 0 up, 0 down | Nov 8, 2024 | $71.74M |
| Jun 30, 2024 | $0.15 | -$0.30 | -$0.34 - -$0.28 | +150.00% | Beat | N/A | 3 | 0 up, 0 down | Aug 2, 2024 | $71.03M |
| Mar 31, 2024 | -$0.01 | -$0.32 | -$0.35 - -$0.30 | +96.88% | Beat | N/A | 3 | 0 up, 0 down | May 3, 2024 | $64.48M |
| Dec 31, 2023 | $0.28 | -$0.29 | -$0.37 - -$0.23 | +196.55% | Beat | N/A | 3 | 0 up, 0 down | Feb 28, 2024 | $70.50M |
| Sep 30, 2023 | -$0.39 | -$0.32 | -$0.35 - -$0.31 | -21.88% | Miss | -750.0% | 2 | 0 up, 0 down | Nov 3, 2023 | $84.69M |
| Jun 30, 2023 | -$0.08 | -$0.33 | -$0.33 - -$0.32 | +75.76% | Beat | -110.3% | 3 | 0 up, 0 down | Aug 4, 2023 | $67.85M |
| Mar 31, 2023 | -$0.22 | -$0.43 | -$0.55 - -$0.34 | +48.84% | Beat | -104.3% | 3 | 0 up, 0 down | May 5, 2023 | $66.17M |
| Dec 31, 2022 | -$0.48 | -$0.56 | -$0.57 - -$0.54 | +14.29% | Beat | -114.4% | 3 | 0 up, 0 down | Feb 28, 2023 | $67.70M |
| Sep 30, 2022 | $0.06 | $0.06 | -$0.06 - $0.17 | 0.00% | In line | -98.5% | 2 | 0 up, 0 down | Nov 7, 2022 | $105.66M |
| Jun 30, 2022 | $0.78 | $0.73 | $0.73 - $0.73 | +6.85% | Beat | -69.9% | 1 | 0 up, 0 down | Aug 4, 2022 | $125.34M |
| Mar 31, 2022 | $5.08 | $3.86 | $3.40 - $4.32 | +31.61% | Beat | -22.1% | 2 | 1 up, 0 down | May 3, 2022 | $320.27M |
| Dec 31, 2021 | $3.34 | $2.61 | $2.49 - $2.67 | +27.97% | Beat | -46.1% | 3 | 1 up, 0 down | Feb 23, 2022 | $251.67M |
| Sep 30, 2021 | $3.93 | $3.25 | N/A | +20.92% | Beat | +88.9% | 2 | 0 up, 0 down | Nov 9, 2021 | $227.87M |
| Jun 30, 2021 | $2.59 | $2.67 | $2.57 - $2.93 | -3.00% | Miss | +1423.5% | 3 | N/A | Aug 9, 2021 | $153.62M |
| Mar 31, 2021 | $6.52 | $5.70 | $5.41 - $6.17 | +14.39% | Beat | N/A | 3 | N/A | May 6, 2021 | $359.43M |
| Dec 31, 2020 | $6.20 | $4.05 | $3.54 - $4.41 | +53.09% | Beat | +15400.0% | 3 | N/A | Mar 4, 2021 | $294.98M |
| Sep 30, 2020 | $2.08 | $0.55 | $0.44 - $0.67 | +278.18% | Beat | +1385.7% | 3 | N/A | Nov 9, 2020 | $101.72M |
| Jun 30, 2020 | $0.17 | $0.01 | -$0.05 - $0.01 | N/A | N/A | +183.3% | 2 | N/A | Aug 4, 2020 | $17.27M |
| Mar 31, 2020 | -$0.03 | $0.02 | $0.02 - $0.02 | -250.00% | Miss | N/A | 1 | N/A | May 4, 2020 | $7.75M |
| Dec 31, 2019 | $0.04 | $0.04 | $0.02 - $0.06 | 0.00% | In line | N/A | 2 | N/A | Mar 10, 2020 | $8.39M |
| Sep 30, 2019 | $0.14 | $0.03 | $0.02 - $0.04 | +366.67% | Beat | N/A | 2 | N/A | Nov 4, 2019 | $10.35M |
| Jun 30, 2019 | $0.06 | -$0.03 | N/A | +300.00% | Beat | N/A | 2 | N/A | Aug 5, 2019 | $8.42M |
| Mar 31, 2019 | -$0.06 | -$0.02 | -$0.03 - -$0.01 | -200.00% | Miss | N/A | 2 | N/A | May 7, 2019 | $5.37M |
| Dec 31, 2018 | -$0.01 | -$0.01 | -$0.04 - $0.01 | 0.00% | In line | N/A | 2 | N/A | Feb 28, 2019 | $5.67M |
| Sep 30, 2018 | -$0.03 | -$0.02 | -$0.04 - -$0.01 | -65.00% | Miss | N/A | 2 | N/A | Nov 6, 2018 | $5.63M |
| Jun 30, 2018 | -$0.01 | -$0.03 | -$0.05 - -$0.01 | +66.67% | Beat | -150.0% | 2 | N/A | Aug 6, 2018 | $5.40M |
| Mar 31, 2018 | -$0.06 | -$0.04 | -$0.06 - -$0.01 | -50.00% | Miss | -300.0% | 2 | N/A | May 7, 2018 | $4.65M |
| Dec 31, 2017 | -$0.06 | -$0.01 | -$0.02 - $0.00 | -500.00% | Miss | -200.0% | 2 | N/A | Feb 28, 2018 | $4.28M |
| Sep 30, 2017 | -$0.02 | $0.02 | $0.02 - $0.03 | -200.00% | Miss | -118.2% | 3 | N/A | Nov 6, 2017 | $4.50M |
| Jun 30, 2017 | $0.02 | $0.02 | $0.01 - $0.02 | 0.00% | In line | N/A | 3 | N/A | Aug 7, 2017 | $4.64M |
| Mar 31, 2017 | $0.03 | $0.06 | N/A | -50.00% | Miss | N/A | N/A | N/A | May 8, 2017 | $5.31M |
| Dec 31, 2016 | $0.06 | $0.04 | N/A | +50.00% | Beat | N/A | N/A | N/A | Feb 27, 2017 | $5.85M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.41, down 16.3% from the year before. It was $0.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.41 | -16.3% |
| Dec 31, 2024 | $0.49 | N/A |
| Dec 31, 2023 | -$0.41 | -107.5% |
| Dec 31, 2022 | $5.44 | -66.8% |
| Dec 31, 2021 | $16.38 | +94.5% |
| Dec 31, 2020 | $8.42 | +4577.8% |
| Dec 31, 2019 | $0.18 | N/A |
| Dec 31, 2018 | -$0.11 | N/A |
| Dec 31, 2017 | -$0.03 | -117.6% |
| Dec 31, 2016 | $0.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,900 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,889 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,851 | 6 | |
| 2026Q1 | Mar 31, 2026 | 4,863 | 7 | |
| 2025Q4 | Dec 31, 2025 | 6,409 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,082 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,498 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,466 | 8 | |
| 2024Q4 | Dec 31, 2024 | 6,046 | 8 |
2026Q3 Earnings Call
Opening remarks
Lauren Sloane Investor Relations Representative Good afternoon, and welcome to Fulgent's third quarter 2026 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the Investor Relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website. Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views, expectations, and assumptions, which may prove to be incorrect. As a result, matters discussed in any forward-looking statements are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ from those described in the forward-looking statements. The company assumes no obligation to update any of the forward-looking statements it may make today to reflect actual results or changes in expectations. Listeners should not rely on any forward-looking statements as predictions of future events and should listen to management's remarks today with the understanding that actual events, including the company's actual future results, may be materially different from what is described in or implied by these forward-looking statements. Please review the more detailed discussions related to these forward-looking statements, including the discussions of some of the risk factors that may cause results to differ from those described in the forward-looking statements, contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10-K for the year ended December 31, 2025, and subsequently filed reports, which are available on the company's Investor Relations website. Management's remarks, including discussions of non-GAAP profit and loss, operating expense, margin, earnings and earnings per share, and adjusted EBITDA, contain financial measures not prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Management has presented these non-GAAP financial measures because it believes they may be useful for investors for various reasons, but these measures should not be viewed as a substitute for or superior to the company's financial results in accordance with GAAP. Please see the company's press release discussing its financial results for the third quarter of 2026 for more information, including the description of how the company calculates non-GAAP income and loss, non-GAAP earnings and loss per share, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating profit and loss and margin, and adjusted EBITDA, and a reconciliation of these financial measures to income and loss, earnings and loss per share, and operating margin, the most directly comparable GAAP financial measures.
Frequently Asked Questions About FLGT
When is Fulgent Genetics's next earnings date?
Fulgent Genetics's next earnings report is expected for Feb 25, 2027.
Did FLGT beat earnings estimates last quarter?
Yes. Fulgent Genetics reported EPS of -$0.09 for the quarter ended Sep 30, 2026, above the -$0.65 estimate, a 86.15% surprise.
What EPS do analysts expect from FLGT next quarter?
The consensus EPS estimate for Fulgent Genetics for the quarter ending Dec 31, 2026 is -$0.69 from 3 analysts.
How often does FLGT beat earnings estimates?
Fulgent Genetics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +121.66%.
FLGT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts